Glioblastoma Clinical Trials in Kansas City, MO

Glioblastoma Clinical Trials in Kansas City, MO

View the best 10 glioblastoma medical studies in Kansas City, Missouri. Access promising new therapies by applying to a Kansas City-based Glioblastoma clinical trial.

Trials in Kansas City, Missouri

Here are the top 10 medical studies for glioblastoma in Kansas City, Missouri

Image of Illinois CancerCare-Bloomington in Bloomington, United States.

Atezolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial tests a combination of tocilizumab, atezolizumab, and precise radiation therapy in patients with recurrent glioblastoma. Tocilizumab reduces inflammation, atezolizumab boosts the immune system, and the radiation targets the tumor. The goal is to make the tumor more responsive to treatment and improve patient outcomes.
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Temozolomide +2 More

Alkylating agents

Recruiting1 awardPhase 2
This trial is studying how well two types of radiation therapy work compared to standard radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma.
Image of Children's Hospital of Alabama in Birmingham, United States.

Tazemetostat

EZH2 Inhibitor

Recruiting1 awardPhase 2
This trial studies how well tazemetostat works in children with certain difficult-to-treat cancers that have specific gene mutations. Tazemetostat is a pill that aims to stop cancer cell growth by blocking a specific protein. The goal is to see if this treatment can help these children when other treatments have failed. Tazemetostat is already approved for treating various cancers, including certain brain tumors in children.
Image of Children's Hospital of Alabama in Birmingham, United States.

Veliparib +2 More

PARP Inhibitor

Recruiting1 awardPhase 2
This trial is studying a combination of drugs as a potential treatment for newly diagnosed malignant glioma. The drugs being studied are veliparib, radiation therapy, and temozolomide.
Image of Littleton Adventist Hospital in Littleton, United States.

Lomustine +2 More

Alkylating agents

Recruiting2 awardsPhase 3
This trial is comparing the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in treating newly diagnosed MGMT methylated glioblastoma.
Image of Barrow Neurological Institute in Phoenix, United States.

Berubicin +1 More

Anthracenedione

Recruiting1 awardPhase 2
This trial will compare the effect of two cancer drugs, berubicin and lomustine, on overall survival in patients with glioblastoma multiforme (GBM) who have failed standard first line therapy. A futility analysis will be performed after approximately 30-50% of planned patients have completed the primary endpoint at 6 months.
Image of Banner MD Anderson in Gilbert, United States.

APL-101

Small Molecule Inhibitor

Recruiting1 awardPhase 2
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Image of University of Kansas Medical Center in Olathe, United States.

TVI-Brain-1 +2 More

CAR T-cell Therapy

Recruiting1 awardPhase 2 & 3
This trial will study an immunotherapy combining a cancer-patient's own cells and standard treatment to fight glioblastoma. Immune cells will be harvested from the patient, stimulated and expanded, then infused back.
Image of Vidant Health in Greenville, United States.

GammaTile radiation therapy implantation +3 More

Brachytherapy

Recruiting3 awardsPhase 4
This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Temozolomide

Alkylating agents

Recruiting0 awardsPhase 2 & 3
This trial is studying the combination of temozolomide and veliparib compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme.

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.